Viz.ai Raises $21 M in Series A Funding From Kleiner Perkins and GV to Increase Patient Access to Proven Therapies

Viz.ai Raises $21 M in Series A Funding From Kleiner Perkins and GV to Increase Patient Access to Proven Therapies

Viz.ai, an applied artificial intelligence (AI) healthcare company focused on time sensitive conditions, has secured $21 million in Series A funding led by Kleiner Perkins, with participation from GV, formerly Google Ventures. Founded in 2016 by Dr. Chris Mansi and Dr. David Golan, Viz.ai has built the first FDA cleared computer aided triage software to detect and triage urgent stroke cases. The AI cloud-based platform analyzes brain scans for large vessel occlusions (LVOs) and sends the scan to a neurovascular specialist to facilitate early therapeutic intervention.

Artificial intelligence will improve medical treatments

Artificial intelligence will improve medical treatments

The potential benefits are great. As Tom Devlin, a stroke neurologist at Erlanger, observes, “We know we lose 2m brain cells every minute the clot is there.” Yet the two therapies that can transform outcomes—clot-busting drugs and an operation called a thrombectomy—are rarely used because, by the time a stroke is diagnosed and a surgical team assembled, too much of a patient’s brain has died. Viz.ai’s technology should improve outcomes by identifying urgent cases, alerting on-call specialists and sending them the scans directly.

New Technology Promises to Speed Critical Treatment for Strokes

New Technology Promises to Speed Critical Treatment for Strokes

The technology from Viz.ai (the ai is for artificial intelligence) recently gained Food and Drug Administration approval. The company and Erlanger are talking to other Chattanooga hospitals about installing its diagnostic software there, which would allow neurologists to see brain scans almost simultaneously.

A Viz.ai study of 300 patients, which prompted the FDA approval, showed that the company’s software was able to notify a stroke neurologist on average 7.3 minutes after the brain imaging took place—compared with the hours that it sometimes takes with conventional diagnostic procedures. The technology accurately identified severe strokes as precisely as expert stroke radiologists do, the study found.

The system holds promise for improved outcomes, medical experts say, but only if it can be widely adopted by hospitals. One concern is cost. Companies developing the technology haven’t set a price but say it won’t be cost-prohibitive.

הנה באה הנבחרת: 20 הסטארטאפים החמים של מגזין TheMarker

הנה באה הנבחרת: 20 הסטארטאפים החמים של מגזין TheMarker

הם פועלים בתחומי הסייבר, האינטרנט של הדברים והמסחר האלקטרוני, וגם בבריאות ובחקלאות - וכולם רוצים לשנות את העולם עם רעיון חדשני והרבה התלהבות. מגזין אלה הסטארטאפים הישראליים שייעצבו את העתיד. לאיזה מהם הפוטנציאל הגדול ביותר? סמנו את הבחירה שלכם

Viz.ai Gets FDA Approval for Early Warning System for Stroke Care

Viz.ai Gets FDA Approval for Early Warning System for Stroke Care

According to the CDC, stroke is the fifth leading cause of death in the US, killing about 140,000 people each year. More than 795,000 people in the US have a stroke each year, adding up to an estimated $34 billion in health care services, medicines to treat stroke and missed days of work. Detecting signs of a potential stroke early can be critically important to preventing long term disability or death. Patients who arrive at the emergency room within three hours of their first symptoms often have less disability than those who received delayed care.

FDA Establishes Precedent by Approving AI-Powered Stroke Triage Software

FDA Establishes Precedent by Approving AI-Powered Stroke Triage Software

The software is a clinical decision support tool that uses artificial intelligence (AI) to analyze CT imaging for indications of stroke. If a suspected large vessel blockage is identified, the algorithm will automatically send a text notification to a neurovascular specialist.

FDA clears Viz.ai's stroke detection software

FDA clears Viz.ai's stroke detection software

February 13, 2018 -- In a move that blazes a regulatory trail for developers of imaging artificial intelligence (AI) software, the U.S. Food and Drug Administration (FDA) has given its blessing to Viz.ai for Contact, an AI-based application that analyzes CT images and notifies providers that a patient might be having a stroke